Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

86.02 +1.40 (+1.65%)
Streaming Delayed Price Updated: 1:10 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Biotech SPDR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
U.S. Weekly FundFlows Insight Report: Sector-Energy Funds Report $1.3 Billion in Outflows, Fourth Largest on Record
During fund-flows week ended June 22, 2022, investors were overall net sellers of fund assets (including both conventional funds and ETFs) for the second straight week, withdrawing a net $20.1... 
Via Talk Markets
3 Beaten-Down ETFs to Buy Before They Rebound
The charts are improving for these fallen angels, and that makes them all top ETFs to buy for the back half of the year. 
Via InvestorPlace
“Should’ve Been Me” Stock Market (And Sentiment Results)
In this week’s AAII Sentiment Survey result, bullish percent ticked down to 18.2% this week from 19.4% last week. 
Via Talk Markets
Option Bears Reloading as Bulls Feeling Spry
As the bulls have their moment, the bears are adding bearish options positions and rolling up into the strength. 
Via Talk Markets
Stock Drop On June 16, But A Rally May Be Coming After Options Expiration
Another miserable day for stocks, with the S&P 500 dropping 3.25% 
Via Talk Markets
The “Shake It Off” Stock Market (And Sentiment Results)
We may be close to a short term peak in yields – bottom in bonds 
Via Talk Markets
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
Crispr and Vertex tested their gene-edited drug in two blood diseases. 
Via Investor's Business Daily
“Chip Shot” Stock Market (And Sentiment Results)
Chips are the key to the economy/inflation moving forward. They are also the key to one of our major new positions in an auto-supplier 
Via Talk Markets
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
Again, Buy ‘Em
Today we discuss again why it’s time to start adding back risk. We cover the major breadth thrusts that fired, some great monthly charts, and more. 
Via Talk Markets
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data... 
Via Benzinga
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than... 
Via Benzinga
This Biotech Looks Good With Increased M&A activity
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for... 
Via Talk Markets
The “Mystery Liquidator Revealed” Stock Market (And Sentiment Results)
In this week’s AAII Sentiment Survey result, Bullish Percent ticked up a hair to 26% this week from 24.3% last week. Bearish Percent rose to 50.4% from 49%. 
Via Talk Markets
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
When Will The Stock Market Stop Falling?
Stocks have fallen dramatically just this past week, is a bottom near? 
Via Talk Markets
Stocks Tank On May 11 With No Bottom In Sight
Despite the sharp decline, the VIX finished down on the day at 32.5. It tells us there was “real” selling in the market today. 
Via Talk Markets
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
Should Biotech Be On The Critical List?
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation. 
Via Talk Markets
“Threading The Needle” Stock Market (And Sentiment Results)
Two weeks ago AAII sentiment survey dropped to a 30 year low at 15.8% bullish. Last week it ticked up modestly to 16.4%. 
Via Talk Markets
7 Monster Stock Market Predictions For The Week Of April 25
The week ending April 22 was brutal. The S&P 500 fell by nearly 2.75%, but things were much worse than that. Powell unleashed hell when he noted that a 50 bps rate hike was on the table for the FOMC... 
Via Talk Markets
The “magic Chart” Stock Market (And Sentiment Results)
We have now come to a point Where the market has priced in more rate hikes than are likely to occur. 
Via Talk Markets
4 Undervalued Biotech Stocks to Add to Your Buy List
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
Healthcare Stocks Lead the Way Up as the Market Fades
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions. 
Via Talk Markets
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. 
Via InvestorPlace
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Sunshine Biopharma Stock Triples on Positive mRNA Cancer Treatment Results
SBFM stock tripled to $6.53 on Tuesday after revealing that two of its newly designed mRNA molecules are effective in destroying cancer cells. 
Via InvestorPlace
Good Entry Point for Biotech Stocks
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms. 
Via Talk Markets
CNBC's Final Call: Newmont, Biotech ETF And This Energy Stock
On CNBC's "The Final Call," Carter Worth recommended Newmont Corporation (NYSE: NEM). The stock has jumped almost 36% year to date. 
Via Benzinga
Acadia: Helping With Alzheimers And Parkinsons
Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.